Challenging the Conventional View of Gut Hormones as Primary Appetite Controllers

In healthy individuals, gut peptide hormones (CCK, PYY, GLP-1) may play a smaller role in normal appetite regulation than traditionally believed, with hedonic and neurocognitive factors potentially being more important.

Crooks, Benjamin et al.·The Proceedings of the Nutrition Society·2021·Moderate EvidenceReview
RPEP-05330ReviewModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
N=not applicable
Participants
Review of enteroendocrine system function in healthy and diseased states

What This Study Found

Postprandial gut peptide hormones may not play a dominant role in normal appetite regulation in healthy individuals; their impact may be more significant in GI disease states where levels become supraphysiological.

Key Numbers

CCK, PYY, GLP-1 discussed; largest endocrine system; hedonic > hormonal in normal appetite; supraphysiological levels in disease

How They Did This

Narrative review of published evidence on enteroendocrine system function, gut peptide hormones, and appetite regulation in health and GI disease.

Why This Research Matters

Billions of dollars are being invested in gut hormone-based therapies for obesity. Understanding the limitations of the gut hormone-appetite connection in healthy individuals may redirect research toward more effective targets.

The Bigger Picture

The success of GLP-1 agonists for weight loss might seem to contradict this review, but the authors note that pharmacological doses far exceed natural postprandial levels. This distinction between physiological and pharmacological effects is crucial for understanding how these hormones work and for developing better obesity treatments.

What This Study Doesn't Tell Us

Narrative review presenting a perspective — not a systematic analysis. The alternative hypothesis (hedonic/cognitive dominance) is also not fully proven.

Questions This Raises

  • ?If gut hormones don't primarily control appetite, why do GLP-1 drugs cause weight loss?
  • ?Could hedonic-targeted therapies be more effective for obesity than gut hormone manipulation?
  • ?Do gut peptides serve primarily as digestive regulators rather than appetite controllers?

Trust & Context

Key Stat:
Largest endocrine system, uncertain appetite role The enteroendocrine system may influence appetite more in disease than in health
Evidence Grade:
Narrative review presenting a provocative hypothesis. Raises important questions but doesn't provide definitive evidence for or against the proposed paradigm shift.
Study Age:
Published in 2021, offering a timely reassessment as GLP-1 agonists gain widespread use for weight management.
Original Title:
Appetite, the enteroendocrine system, gastrointestinal disease and obesity.
Published In:
The Proceedings of the Nutrition Society, 80(1), 50-58 (2021)
Database ID:
RPEP-05330

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Do gut hormones really control how hungry you feel?

This review suggests they may not play as big a role as traditionally thought in healthy people. While gut hormones like GLP-1 and PYY rise after meals, the evidence that these natural levels actually control your appetite is weaker than commonly believed. Pleasure-seeking and psychological factors may matter more for normal eating.

If gut hormones don't control appetite, why do GLP-1 drugs help with weight loss?

The key is dose. GLP-1 drugs like semaglutide deliver far higher levels than the body produces naturally after a meal. At these pharmacological doses, appetite suppression is dramatic. But the natural postprandial levels of these hormones may not be the primary drivers of everyday appetite in healthy people.

Read More on RethinkPeptides

Cite This Study

RPEP-05330·https://rethinkpeptides.com/research/RPEP-05330

APA

Crooks, Benjamin; Stamataki, Nikoleta S; McLaughlin, John T. (2021). Appetite, the enteroendocrine system, gastrointestinal disease and obesity.. The Proceedings of the Nutrition Society, 80(1), 50-58. https://doi.org/10.1017/S0029665120006965

MLA

Crooks, Benjamin, et al. "Appetite, the enteroendocrine system, gastrointestinal disease and obesity.." The Proceedings of the Nutrition Society, 2021. https://doi.org/10.1017/S0029665120006965

RethinkPeptides

RethinkPeptides Research Database. "Appetite, the enteroendocrine system, gastrointestinal disea..." RPEP-05330. Retrieved from https://rethinkpeptides.com/research/crooks-2021-appetite-the-enteroendocrine-system

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.